Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Consensus Recommendation of “Hold” by Brokerages

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been given an average rating of “Hold” by the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $70.75.

Several brokerages recently weighed in on PBH. Weiss Ratings lowered Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday, May 14th. Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Jefferies Financial Group cut their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Finally, Canaccord Genuity Group cut their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the transaction, the vice president owned 42,820 shares in the company, valued at $2,354,671.80. The trade was a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently modified their holdings of PBH. UMB Bank n.a. increased its stake in Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after buying an additional 219 shares in the last quarter. Bayforest Capital Ltd purchased a new stake in Prestige Consumer Healthcare during the 4th quarter worth approximately $29,000. First Horizon Corp purchased a new stake in Prestige Consumer Healthcare during the 3rd quarter worth approximately $32,000. Barrow Hanley Mewhinney & Strauss LLC increased its stake in Prestige Consumer Healthcare by 106.8% during the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after buying an additional 283 shares in the last quarter. Finally, Torren Management LLC purchased a new stake in Prestige Consumer Healthcare during the 4th quarter worth approximately $35,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $48.02 on Monday. The stock has a market cap of $2.27 billion, a PE ratio of 12.28, a price-to-earnings-growth ratio of 1.54 and a beta of 0.40. The business has a 50-day simple moving average of $55.97 and a 200-day simple moving average of $60.90. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. Prestige Consumer Healthcare has a 52-week low of $42.62 and a 52-week high of $87.12.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.39 by ($0.16). The company had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The business’s quarterly revenue was down 5.0% compared to the same quarter last year. During the same period last year, the firm earned $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, equities analysts expect that Prestige Consumer Healthcare will post 4.45 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).